Reflections and Future Directions in CLL Management

Video content above is prompted by the following:

• Briefly comment on the increasing preference for fixed-duration therapy over treatment until progression, as reflected in recent guideline updates:
  • How do you view the balance between fixed-duration and treat-to-progression approaches?
  • How might strategies continue to evolve, and what implications could it have for future treatment practices?

• Before we wrap up, I’d like to hear your final thoughts and reflections on the strides we made throughout 2024—including new/exciting data presented at ASH 2024.
  Let’s consider what opportunities/what we are looking forward to ahead in 2025. Points to consider:
  • What accomplishments in CLL are you most proud of?
  • Which developments stand out as pivotal in shaping clinical practice?
  • What are you most excited about in 2025?
  • What areas are primed for significant progress? What do you hope to achieve in the coming year?